Neonatal stroke is a condition that leads to disability in later life, and as yet there is no effective treatment. Recently, erythropoietin (EPO) has been shown to be cytoprotective following brain injury and may promote neurogenesis. However, the effect of EPO on functional outcome and on morphologic changes in neonatal subventricular zone (SVZ) following experimental neonatal stroke has not been described. We used a transient focal model of neonatal stroke in P10 rat. Injury was documented by diffusion weighted MRI during occlusion. Immediately upon reperfusion, either EPO (5U/gm) or vehicle was administered intraperitoneally and animals were allowed to grow for 2 wk. Sensorimotor function was assessed using the cylinder rearing test and then brains were processed for volumetric analysis of the SVZ. Stroke induced SVZ expansion proportional to hemispheric volume loss. EPO treatment markedly preserved hemispheric volume and decreased the expansion of SVZ unilaterally. Furthermore, EPO treatment significantly improved the asymmetry of forelimb use following neonatal stroke. This functional improvement directly correlated with the amount of preserved hemispheric volume. These results suggest EPO may be a candidate in the treatment of neonatal stroke. Stroke is recognized in about 1 in 4000 full-term infants (1). Stroke during the perinatal or early postnatal period affects CNS development and leads to lifelong neurologic morbidity such as cerebral palsy. However, there are as yet no clear evidence-based strategies for treatment (2).
Neonatal stroke is a condition that leads to disability in later life, and as yet there is no effective treatment. Recently, erythropoietin (EPO) has been shown to be cytoprotective following brain injury and may promote neurogenesis. However, the effect of EPO on functional outcome and on morphologic changes in neonatal subventricular zone (SVZ) following experimental neonatal stroke has not been described. We used a transient focal model of neonatal stroke in P10 rat. Injury was documented by diffusion weighted MRI during occlusion. Immediately upon reperfusion, either EPO (5U/gm) or vehicle was administered intraperitoneally and animals were allowed to grow for 2 wk. Sensorimotor function was assessed using the cylinder rearing test and then brains were processed for volumetric analysis of the SVZ. Stroke induced SVZ expansion proportional to hemispheric volume loss. EPO treatment markedly preserved hemispheric volume and decreased the expansion of SVZ unilaterally. Furthermore, EPO treatment significantly improved the asymmetry of forelimb use following neonatal stroke. This functional improvement directly correlated with the amount of preserved hemispheric volume. These results suggest EPO may be a candidate in the treatment of neonatal stroke. Stroke is recognized in about 1 in 4000 full-term infants (1) . Stroke during the perinatal or early postnatal period affects CNS development and leads to lifelong neurologic morbidity such as cerebral palsy. However, there are as yet no clear evidence-based strategies for treatment (2) .
We previously developed a nonhemorrhagic ischemic stroke model in immature rat by transient MCAO (3, 4) , which can be used for testing treatment strategies for neonatal ischemic stroke. Recent studies indicate that EPO plays an important role in neuronal survival after injury in a variety of models in mature and immature rodent brain. Not only direct intracerebroventricular injection (5-7) but also systemic administration of rhEPO significantly reduced the infarct volume following MCAO in adult rodent (8, 9) and in a hypoxia-ischemia model in the neonatal animal (7,10 -12) . Permanent focal brain ischemia activates EPO receptor in neonatal brain (13) and exogenous rhEPO is protective in that model (14) , suggesting EPO may play an important role in ischemic injury in developing brain.
To be a promising neuroprotective therapy, not only improved histology but also improved neurologic function has to be demonstrated. Kumral et al. (15) reported that systemic administration of EPO in neonatal animals immediately after cerebral hypoxia-ischemia improved long-term spatial memory deficits. However, there is as yet no published data for the effect of EPO on brain protection and on improving sensorimotor deficit after pure ischemic stroke in the neonatal animal.
EPO is known to promote neurogenesis in vitro (16) , and recently Wang et al. (17) reported EPO enhanced neurogenesis in SVZ after stroke in the adult rodent. The SVZ in rodent forebrain is the germinative area for newly generated olfactory bulb neurons throughout life (18) . Focal ischemic injury stimulates precursor proliferation and increases the size of adult rodent forebrain SVZ (19, 20) . Regarding the SVZ of neonatal rodent brain, little is known and controversies exist. Some studies have reported depletion of neural stem cells in SVZ after hypoxia-ischemia (21, 22) . On the contrary, a recent report from Plane et al. (23) showed that hypoxia-ischemia in neonatal mouse augmented the SVZ size similar to the adult. Furthermore, they showed that severity of injury induced by hypoxia-ischemia is directly related to the degree of expansion of neonatal SVZ.
The changes in neonatal SVZ after pure ischemic stoke in newborn animals are unknown, and the effect of exogenous administration of EPO on neonatal SVZ has not been demonstrated. Therefore, we performed analysis of neonatal SVZ volume and sensorimotor function after focal ischemiareperfusion injury in immature postnatal day (P) 10 rats treated with EPO or vehicle to elucidate the response of the neonatal SVZ to ischemic injury and to investigate the therapeutic potential of exogenous EPO in neonatal ischemic stroke.
METHODS
All animal research was approved by the University of California, San Francisco Institutional Animal Care and Use Committee and was performed in strict accordance with the relevant National Institutes of Health guidelines. Every effort was made to minimize animal suffering and to reduce the number of animals used.
Cerebral focal ischemia: reperfusion and treatment. All surgical procedures were performed in 10-d-old Sprague-Dawley rats. P10 rats were chosen for this neonatal stroke model to more accurately approximate the development of the term human newborn (24) . Female Sprague-Dawley rats with an 8 -9-d-old litter (9 -10 pups per litter) were bought from Simonson Labs (Gilroy, CA). The mother was given food and water and housed in a temperature-and light-controlled facility until the pups were 10 d old. Transient focal cerebral ischemia was produced using the MCAO model with some modifications, as published before (4, 25) . Briefly, each pup was weighed and anesthetized with 3% isoflurane in a mixture of 70% N 2 O and 30% O 2 . After induction of anesthesia, 1.5% isoflurane was maintained. Because P10 pups have not developed thermoautoregulation, rectal temperature was monitored and maintained at 36 -37°C with a combination of overhead lights and a heating blanket. With the animal supine, the right common carotid artery (CCA), external carotid artery (ECA), and internal carotid artery (ICA) were exposed with a midline cervical incision. The pterygopalatine, occipital, superior thyroid, maxillary, and lingual arteries were coagulated. After ligation of the ECA, a 5-0 nylon monofilament suture with blunted tip was inserted into the ECA lumen and gently advanced through the ICA up to the middle cerebral artery until slight resistance was felt. After placement of the suture, the wound was closed. Sham controls did not have the suture advanced.
Magnetic resonance imaging. Each animal was examined by diffusionweighted spin echo planar imaging (SE EPI) at 20 -30 min after MCAO to eliminate animals with inadequate or atypical injury patterns. The entire brain was imaged with serial 20mm-thick coronal sections as previously described (3) using the following pulse sequence settings: TR/TE ϭ 5000/60 ms, 4 averages, field of view (FOV) ϭ 35 mm, data matrix 128 ϫ 128, diffusion gradient duration ϭ 20 ms, separation ϭ 29.7 ms, amplitude ϭ 70 mT/m, b-factor ϭ 1045 s/mm 2 . Pups that exhibited ischemic injury in atypical regions, such as brainstem, or that showed lack of cortical involvement were excluded from the study. In a preliminary study, we found that an occlusion time of 45 min produced a moderate level of injury. Reperfusion was achieved after 45 min of occlusion by removing the suture under general anesthesia. Two of the MCAO animals were imaged during the transit of bolus-injected DyDTPA-BMA before and 20 min after removing the suture to confirm complete disruption of cerebral blood flow during occlusion and partial restoration of blood flow after reperfusion.
Immediately upon reperfusion, either vehicle [0.1% BSA (Sigma Chemical Co., St. Louis MO) in saline] or rhEPO (a generous gift from Johnson & Johnson) at a dose of 5 units per gram of body weight were injected intraperitoneally. Sham animals were also injected with vehicle or EPO after sham surgery. After the injection, animals recovered from anesthesia and were returned to their dam for 2 wk.
Sensorimotor function: cylinder test. All rats were evaluated for sensorimotor asymmetry at 2 wk after surgery (P24) with the cylinder test (26) . Rats could explore the walls of the cylinder as early as P21 (26) . The apparatus was a cylinder of transparent Plexiglas and measured 20 cm in diameter and 30 cm in height (27) . The cylinder was high enough so that the animal could not reach the top edge of the apparatus by rearing. The width of the cylinder allowed the animal to be freely moving horizontally. The cylinder was sufficiently heavy that it did not move when the animal supported its weight against the wall. Animals were handled for about 10 min per day 3 d before testing. Each animal was individually placed in the cylinder and observed for 3 min. Initial forepaw of each weight-bearing contact with the wall during a full rear was recorded, or "both" were recorded for simultaneous contact with both forepaws. Nonimpaired (right, ipsilateral) or impaired (left, contralateral) percentage of total forepaw contacts at initiation was calculated. Percentage difference between nonimpaired and impaired paw initiation was calculated as the percentage nonimpaired initiation subtracted from the percentage impaired forepaw initiation. All scoring was done by raters who were unaware of treatment group assignment. All animals were scored twice by two independent raters and the average scores of the two raters were used for data analysis.
Histology. For histopathologic examination, after cylinder testing, animals were anesthetized with sodium pentobarbital (100 mg/kg) (Nembutal, Abbott Labs, Abbott Park, IL), and killed at P24 by transcardiac perfusion with ice-cold 4% paraformaldehyde in 0.1 M PBS (pH 7.4). Brains were carefully removed and postfixed overnight, equilibrated in 30% sucrose in 0.1 M PBS and left at 4°C up to a maximum of 72 h. Free-floating serial 40 um coronal sections were collected throughout the brain in each animal on a freezing microtome. The sections were stored at 4°C in 0.1 M phosphate buffer with 0.1% sodium azide for a maximum of 2 wk and then stored in cryoprotectant at -20°C until staining. The mounted sections were air-dried, stained with cresyl violet, dehydrated in graded ethanol solutions, cleared in Citrosolv (Fisher Scientific, Pittsburgh, PA), and cover-slipped in Permount (Fisher Scientific).
Stereologic volumetric analyses of bilateral hemisphere and SVZ. Using systematic random sampling, a series representing every 12th section was selected, cresyl violet stained, and analyzed. All volumetric quantifications were performed with a Nikon Eclipse E600 photomicroscope equipped with a high-resolution CCD camera, a motorized XYZ axis computer-controlled stage, and Neurolucida and Neuroexplorer morphometry software package (MicroBrightField, Inc., Colchester, VT). When calculating the volume, the cross-sectional areas of region of interest (ROI) in each section was traced on the computer screen at low power using a 2ϫ/4ϫ lens and the volume of ROI was calculated according to the Cavalieri principle (28) . Sections encompass the whole striatum rostrally from the genu of the corpus callosum and caudally to the rostral part of the hippocampus corresponding to plates 9 -24 of Paxinos' rat brain atlas (29) . For the ROI, right and left hemisphere and SVZ were traced. Morphologic criteria were used consistently in all animals to determine the boundaries of SVZ. Dorsolateral striatal extension of SVZ, which resembles the dark band and thin long triangle in the sections corresponding to plates 10 -20, was outlined. Briefly, the superior-medial boundary of SVZ was defined by the corpus callosum, the lateral boundary by the striatum, and the inferior boundary by the lateral ventricular margin. By using this sampling strategy, approximately 11 histologic sections per brain for hemispheric measurement and approximately 6 sections per brain for SVZ measurement were analyzed. Quantification was conducted blind by an examiner unaware of treatment group. Damage due to stroke was determined quantitatively by calculating the percentage preserved volume in the lesioned versus the control hemisphere. Size alteration of SVZ was investigated by calculating the percent SVZ volume in lesioned versus control hemisphere in each animal.
Data analysis. Data are presented as mean Ϯ SD. For statistical analysis, nonparametric methods were used. Kruskal-Wallis test was done for comparisons of multiple groups followed by the Wilcoxon rank sum test including a Bonferroni adjustment for comparison between two groups. Pearson correlation coefficients compared statistical relationships. All statistical analyses described above were done using SAS software program version of 6.12 (SAS Institute, Cary, NC). p Values below 0.05 were considered significant.
RESULTS
Injury assessment. For this study, 16 animals received transient MCAO and sham surgery was performed in 8 animals. According to the inclusion criterion by imaging of diffusion weighted MRI, 13 of 16 animals were included and allocated randomly to MCAO with vehicle (n ϭ 7) or MCAO with EPO treatment (n ϭ 6). Most of the pups at P10 given MCAO showed poor sucking, especially for the first 2 or 3 d after surgery. One pup from the EPO-treated MCAO group and two pups from the vehicle-treated MCAO group died during the following 2 wk before the analysis. No animal died during or immediately after the procedure. Therefore, 18 animals survived; sham surgery with vehicle (n ϭ
Animals given transient MCAO showed significant tissue loss in the striatum and parietotemporal cortex ipsilateral to MCAO at 2 wk after surgery. For quantitative measurement of injury severity, the ratio of intact ipsilateral hemisphere volume to contralateral hemisphere volume was calculated. Despite reports that EPO promotes neurogenesis, in the animals given sham surgery, EPO treatment did not affect the volume of the hemispheres (Fig. 1A) . In vehicle-treated animals at 2 wk after MCAO surgery, there was significant decrease in percentage preserved volume compared with sham animals (p Ͻ 0.05). Animals that received EPO had a marked protective effect compared with vehicle treated MCAO animals (p Ͻ 0.05) (Fig.  1B) .
Assessment of SVZ changes. Cresyl Violet-stained sections revealed the definite demarcation of SVZ in the dorsolateral aspect of the lateral ventricle (Fig. 2) . In sham animals treated with vehicle (Fig. 2, A and E) versus those treated with EPO (Fig. 2, B and F) , there were no differences in the morphology of SVZ. In the rostral section (corresponding to Plate 10 of Paxinos' rat brain atlas) (29) , the SVZ revealed a narrow, intensely stained band between the corpus callosum and subcallosal striatum adjacent to the striatal ventricular margin. The SVZ widened dorsolaterally and showed a dorsolateral tail beneath the corpus callosum through caudal sections (corresponding to Plate 20 of Paxinos' rat brain atlas) (29) . Transient MCAO induced remarkable morphologic changes in the ipsilateral SVZ, with marked expansion rostrally and laterally in more rostral sections (Fig. 2C) , and showed a more triangular shape in more caudal sections resulting from ipsilateral striatal atrophy and corresponding widening of the lateral ventricle (Fig. 2G) . EPO treatment significantly decreased these morphologic changes (Fig. 2, D and H) . When we measured the SVZ volume on the contralateral side to the MCAO or in shams, there were no statistical differences among the four groups (data not shown). To evaluate the degree of expansion of ispsilateral SVZ, the percentage volume ratio of SVZ ipsilateral over contralateral to MCAO was calculated. Vehicletreated MCAO animals showed significantly increased percentage volume of ispilateral SVZ compared with the sham operated animals (p Ͻ 0.05). EPO treatment significantly decreased this ipsilateral SVZ enlargement (p Ͻ 0.05) (Fig.  3A) . For the evaluation of the relationship between the degree of SVZ expansion and the degree of tissue damage, the ratio of percentage hemispheric volume and percentage SVZ volume as described was compared and revealed an inverted linear relationship with the coefficients of simple determination of 0.3525 (r 2 ) (p Ͻ 0.02) (Fig. 3B ). Behavior test with cylinder rearing. To evaluate the lateralizing sensorimotor deficit, the percentage of weight-bearing episodes that were initiated with the nonimpaired (ipsilateral) forepaw (Fig. 4A ) and the percentage difference between nonimpaired (ipsilateral) and impaired (contralateral) forepaw initiation (Fig. 4B) was calculated in each animal at P24 before sacrificing them for brain evaluation. As expected, sham animals showed symmetrical use of bilateral paw when rearing, and percentage ipsilateral and contralateral paw initiation was around 20%.
MCAO animals showed marked asymmetry due to the preference for the use of nonimpaired, ipsilateral paw when rearing, compared with sham (p Ͻ 0.01). EPO treatment significantly improved this asymmetry compared with vehicle-treated MCAO animals (p Ͻ 0.05). When we compared the percentage hemisphere volume ipsilateral versus contralateral and percent- (Fig. 4C) .
DISCUSSION
These results show that EPO is protective after ischemic stroke in immature animals, both by ameliorating brain tissue loss and improving sensorimotor function. This study also indicates that focal ischemia-reperfusion injury increases the size of the ipsilateral forebrain neonatal SVZ, suggesting that precursor proliferation is involved in the response of the neonatal brain to ischemic injury. Furthermore, this effect is directly correlated with injury severity, such that animals with more severe injury had a greatly expanded SVZ. Therefore, attenuated expansion of forebrain SVZ in EPO-treated animals in this study can be explained by injury reduction exerted by EPO after transient MCAO in immature rats. Importantly, systemic EPO did not have a growth factor effect in normal or sham operated brains.
EPO is known as one of the major target genes of hypoxia inducible factor 1 (HIF-1), an oxygen-sensing molecule in tissue including brain (30, 31) . We previously demonstrated that HIF-1 is induced in our model (4) . Expression of EPO and EPO receptor has been demonstrated in ischemic neonatal brain after hypoxia-ischemia (12) and permanent MCAO (13) . The mechanism of EPO protection in ischemic brain in the mature animal is thought to be due to penumbral activation of EPO receptor. Binding of EPO to its receptor generates an anti-apoptotic cascade (9, 32, 33) . Therefore, if the penumbral region is larger, the cytoprotectant effect of EPO will be greater (34) . In the adult rodent, whereas EPO significantly decreased the infarct size after transient MCAO (8) , histologic reduction of infarct size was not seen after more severe injury as in permanent MCAO (17) .
As our group reported previously, in this transient stroke model in an immature animal, there is no clear demarcation of penumbra and core in injured tissue (35) . Neuronal caspase-3 activation occurred robustly in both the ischemic core and penumbra in our P7 rat model. These findings support the speculation that the cytoprotection by EPO through antiapoptotic action may be greater in immature brain after transient stroke. The mechanism of EPO protection must be clarified with further study.
Several studies have reported that systemic administration of rhEPO reduced brain injury in neonatal models, including hypoxia-ischemia (7,10 -12,15) and N-methyl-D-aspartate receptor antagonist neurotoxicity (36) . Although these studies have reported tissue protection with EPO treatment, a sensorimotor functional outcome has not been evaluated. Forepaw placement in cylinder rearing is a well-known test in the adult rodent as a measure of forelimb function (37) (38) (39) (40) . Particularly, asymmetry of forelimb wall contact is considered an index of motor system integrity and is widely used in adult rodent MCAO models (39, 40) . The cylinder test is simple, reliable, and reproducible. However, possible limitations have to be considered in the detection of lateralizing sensorimotor deficits originating in the neonatal period. At this age, animals are still immature in regard to motor function. Another limitation is that, with the serial monitoring for function over time, the sensitivity of the test can be decreased due to learning and functional recovery during that period (41) . Grow et al. (26) have reported that the cylinder test in P35 rat could detect sensorimotor deficits after hypoxia-ischemia and correlated well with cortical striatal damage. We performed the cylinder test at P24 and revealed that it was sensitive enough to detect limb use asymmetry at this age and the asymmetry of limb use directly correlated with the extent of brain damage. To our knowledge, this study is the first report of improvement in sensorimotor function by EPO treatment in neonatal animals after ischemic brain damage. For the documentation of longterm functional recovery, follow-up studies are underway.
The SVZ in rodent forebrain contains neuronal precursor cells throughout life. Various types of injury stimulate the proliferation of SVZ precursor cells in adult rodent brain, and it is believed that stem cells in neurogenic areas respond to injury (42) . Increase in size of SVZ and proliferation of neuronal precursor cells has been demonstrated in adult rodent after MCAO (19, 20) . Several studies suggest that specific growth or neurotrophic factors, such as IGF-1 and brainderived neurotrophic factor (BDNF), influence neural precursor proliferation in the adult rodent brain (43, 44) . Inflammatory reactions in the CNS can produce various neurotrophic factors such as brain-derived neurotrophic factor, nerve growth factor, and neurotrophins 3 and 4/5 (45). These observations support our results demonstrating that focal ischemia-reperfusion injury stimulates SVZ expansion in neonatal rodent brain. Our finding also corresponds with the recent report of Plane et al. (23) that showed a significant increase in SVZ area after hypoxia-ischemia in P10 mice.
EPO is also known to have neurotrophic actions both in vivo and in vitro (16) . For example, EPO treatment increases proliferation of precursor cells of SVZ area in permanent MCAO in adult rodent (17) . However, in that study, EPO did not decrease the infarct size, which is an important difference from our study. We demonstrated that the animals with more injury Levison et al. (21) reported that hypoxia-ischemia depleted the SVZ and precursor cells. The differences from our results may be derived from the injury severity and model difference. Another difference may be derived from the method used to evaluate SVZ. We evaluated the volume of SVZ including the entire rostral to caudal extent, whereas the study of Levison et al. evaluated the stem cell population of SVZ mainly at the level of the anterior commissure, which is the more caudal part of SVZ. Recently Romanko et al. (47) reported that the medial part of dorsolateral SVZ is resistant to hypoxic-ischemic injury. In this study, we calculated the total SVZ volume using stereologic principles that are unaffected by the possibility of uneven sectioning through damaged tissue and compared ipsilateral versus contralateral to correct for interanimal differences in SVZ size. We observed that the rostral part of SVZ is more markedly expanded compared with the caudal part of SVZ, because we cannot detect size difference caudally because of marked changes in morphology due to enlargement of the lateral ventricle. Caution is needed in interpreting the effect of EPO on neonatal SVZ after ischemic injury, because we investigated only the morphologic change of SVZ, not the proliferation of precursor cells in SVZ.
In our study, two hypotheses may be considered for these actions of EPO. First, EPO is directly cytoprotective and preserved brain tissue is responsible for improved functional outcome. Second, EPO stimulates neurogenesis, repopulating injured brain tissue and improving functional outcome. Our observation that EPO attenuated expansion of forebrain SVZ is more consistent with the first hypothesis. However we cannot rule out the possibility that EPO influences cell fate decisions among the progeny of mitotic precursor cells in the SVZ, shifting the response toward the generation of neurons. Studies to answer this important question are underway. Of course, these two hypotheses are not mutually exclusive and both may represent important mechanisms for protection and recovery after neonatal ischemic brain injury.
We did not examine the effect of EPO on erythropoiesis in this study. A recent report has shown that derivatives of EPO can be tissue protective but not erythropoietic, which may be detrimental following stroke (46) .
In our model of neonatal ischemic stroke, proven by diffusion weighted MRI, EPO preserved brain volume and improved sensorimotor function. EPO therefore is an excellent candidate for the treatment of neonatal stroke, one of the most devastating conditions occurring during the neonatal period. 
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